The incorporation of anti-IFN-α AAb screening, particularly functional neutralization assays, into early diagnostic algorithms for COVID-19 may enable clinicians to anticipate disease trajectories, escalate monitoring, and guide the early use of immunomodulators. This evidence concerns the gene IFNA2 and COVID-19.